References
- Lee M S, Chang K S, Cabanillas F, Freireich E J, Trujillo J M, Stass S A. Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science 1987; 237: 175–178
- Gribben J G, Freedman A, Woo S D, et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 78: 3275–3280
- Gribben J G, Neuberg D, Barber M, et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 1994; 83: 3800–3807
- Janikova A, Mayer J, Kren J, et al. The persistence of t(14;18)-bearing cells in lymph nodes of patients with follicular lymphoma in complete remission: the evidence for ‘a lymphoma stem cell’. Leuk Lymphoma 2009; 50: 1102–1109
- Darby A J, Lanham S, Soubeyran P, Johnson P W. Variability of quantitative polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicenter study. Haematologica 2005; 90: 1706–1707
- Corradini P, Ladetta M, Zallio F, et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004; 22: 1460–1468
- López-Guillermo A, Cabanillas F, McLaughlin P, et al. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol 2000; 11(Suppl 1)137–140
- Rambaldi A, Carlotti E, Oldani E, et al. Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood 2005; 105: 3428–3433
- Sacchi S, Pozzi S, Marcheselli R, et al. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Cancer 2007; 110: 121–128
- Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101–106
- Bendandi M, Gocke C D, Kobrin C B, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5: 1171–1177
- Mandigers C MPW, Meijerink J PP, van't Veer M B, Mensink E JBM, Raremaekers J MM. Dynamics of circulating t(14;18)-positive cells during first-line and subsequent lines of treatment in follicular lymphoma. Ann Hematol 2003; 82: 743–749
- Schmitt C, Grundt A, Buchholtz C, et al. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: is the end of molecular monitoring near. Leuk Res 2006; 30: 1563–1568
- Czuczman M S, Weaver R, Alkuzweny B, Berlfein J, Grillo-López A. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 4711–4716
- Arcaini L, Montanari F, Alessandrino E P, et al. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol 2008; 19: 1331–1335
- Aiello A, Delia D, Giardini R, et al. PCR Analysis of IgH and BCL2 gene rearrangement in the diagnosis of follicular lymphoma in lymph node fine-needle aspiration. A critical appraisal. Diagn Mol Pathol 1997; 6: 154–160